UMRX | Unum Therapeutics Inc.
Unum Therapeutics is a biopharmaceutical company focused on developing curative cell therapies to treat patients with advanced cancers. Unumâs novel proprietary technology called Bolt-On Chimeric Receptor (BOXR) is designed to improve the functionality of engineered T cells by discovering and incorporating a âbolt-onâ transgene into a patientsâ engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Unumâs BOXR1030, the first preclinical product candidate to emerge from the BOXR platform, is composed of a GPC3-targeted CAR T cell and a âbolt-onâ enzyme called glutamic-oxaloacetic transaminase 2 (GOT2) that aims to improve T cell function in the solid tumor microenvironment through enhanced metabolism. GOT2 plays a central metabolic role by linking multiple pathways involved in biosynthesis and cellular energy production.
200 Cambridge Park Drive
If you are looking for News & events, Press Release, they are available on their Investors Relationssite.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
While many books explain the how of bitcoin, The Internet of Money delves into the why of bitcoin. Acclaimed information-security expert and author of Mastering Bitcoin, Andreas M. Antonopoulos examines and contextualizes the significance of bitcoin through a series of essays spanning the exhilarating maturation of this technology.